secwatch.observer — SEC 8-K summary
======================================

Issuer:     Curanex Pharmaceuticals Inc (CURX)
CIK:        0002025942
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001493152-25-012316
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curanex Pharmaceuticals prices IPO of 3.75M shares at $4.00/share, gross $15M
-----------------------------------------------------------------------------

- Gross proceeds $15M from 3.75M shares at $4.00/share; net proceeds ~$12.1M after underwriting discounts and expenses.
- Shares expected to begin trading on Nasdaq (CURX) on Aug 26, 2025; close expected Aug 27, 2025.
- Underwriters have 45-day option to purchase up to 562,500 additional shares to cover over-allotments.
- Proceeds to fund Phyto-N (ulcerative colitis) development, GLP toxicology/pharmacokinetic studies, IND submission, and working capital.
- Lead underwriter: Dominari Securities; co-underwriters: Pacific Century Securities and Revere Securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2025942/000149315225012316/0001493152-25-012316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2025942/000149315225012316/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-012316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer